In particular, the association between Neanderthal-derived variants of GLP1R and T2D is intriguing, considering population specificity and the development of oral semaglutide, a glucagon-like peptide-1 (GLP-1) analog, for treating T2D (91). The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.